Loading clinical trials...
Loading clinical trials...
B- PRISM (Precision Intervention Smoldering Myeloma): A Phase II Trial of Combination of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High- Risk Smoldering Multiple Myeloma
Conditions
Interventions
Daratumumab
Bortezomib
+2 more
Locations
6
United States
Stamford Hospital
Stamford, Connecticut, United States
Brigham and Women's Hospital
Boston, Massachusetts, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Dana-Farber Brigham Cancer Center - Foxborough
Foxborough, Massachusetts, United States
Dana-Farber Cancer Institute - Merrimack Valley
Methuen, Massachusetts, United States
Dana-Farber Brigham Cancer Center
South Weymouth, Massachusetts, United States
Start Date
March 8, 2021
Primary Completion Date
December 20, 2026
Completion Date
December 8, 2030
Last Updated
July 2, 2025
NCT06152575
NCT06179888
NCT04973605
NCT05201781
NCT06138275
NCT05862012
Lead Sponsor
Omar Nadeem, MD
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions